Our findings demonstrate that DZNep-mediated EZH2 inhibition reduces inflammation by suppressing the release of pro-inflammatory cytokines and T cell infiltration during both early and late post-transplantation periods, ultimately reducing the severity of BOS. This evidence concerns the gene EZH2 and Buschke-Ollendorff syndrome.